New hope for hemophilia patients with inhibitors: STSP-0601 enters phase 3 trial
NCT ID NCT06922045
First seen Jun 26, 2026 · Last updated Aug 13, 2026 · Updated 3 times
Summary
This Phase 3 trial is testing STSP-0601, an injectable drug, to control bleeding episodes in people with hemophilia A or B who have developed inhibitors (antibodies that block standard treatment). The study will enroll 40 participants aged 12 to 70 and measure how well the drug stops bleeding within 12 hours. If effective, STSP-0601 could offer a new way to manage bleeds in this challenging patient group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- STSP-0601 injection
- What this could lead to
- If successful, this could provide a new treatment option to control bleeding episodes in hemophilia patients with inhibitors, reducing the need for other therapies.
- What could go wrong
- This is a small Phase 3 trial with only 40 participants, so results may not apply to all patients. The drug may not achieve effective hemostasis in all cases, and side effects are still being evaluated.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHILIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Anhui Provincial Hospital
Hefei, Anhui, 230001, China
-
Harbin First Hospital Hematology Tumor Research Center
Harbin, Heilongjiang, 150000, China
-
Henan Cancer Hospital
Zhengzhou, Henan, 300020, China
-
Hospital of Hematology, Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, 300020, China
-
Huazhong University of Science and Technology Union Hospital
Wuhan, Hubei, 430022, China
-
Jiangsu Provincial Hospital
Nanjing, Jiangsu, 210029, China
-
Jinan Central Clinical College of Shandong First Medical University
Jinan, Shandong, 250013, China
-
Lanzhou University First Hospital
Lanzhou, Gansu, 730000, China
-
Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, 510515, China
-
North China University of Science and Technology Affiliated Hospital
Tangshan, Hebei, 063000, China
-
Second hospital of Shanxi Medical University
Taiyuan, Shanxi, 030001, China
-
Shenzhen Second People's Hospital
Shenzhen, Guangdong, 518000, China
-
Sichuan Academy of Medical Sciences＆Sichuan Provincial People's Hospital
Chengdu, Sichuan, 610072, China
-
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, 330000, China
-
The First affiliated hospital of Guangxi Medical University
Nanning, Guangxi, 530021, China
-
The Second Affiliated Hospital of Kunming Medical University
Kunming, Yunnan, 650000, China
-
Wenzhou People's Hospital
Wenzhou, Zhejiang, 325000, China
-
Xi'an Central Hospital
Xi’an, Shanxi, 710000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a clotting boost make surgery safer for hemophilia patients?
- A facelift without the bruising? tranexamic acid put to the test.
- Deep gum cleaning may boost quality of life for hemophilia patients
- Can a video call replace the clinic for hemophilia pain relief?
- Experimental drug aims to reverse liver damage in rare triple condition
- Monthly shot could free kids with hemophilia from frequent infusions